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SUMMARY
Background: Retinobalstoma, the commonest 
childhood malignant intraocular tumour, is usually 
diagnosed early with over 90% survival rate in 
developed countries.  In developing countries, the 
diagnosis is late resulting in less than 50% survival. 
Objective: To determine retinoblastoma stages at 
presentation and patients’ outcomes. 
Design: Retrospective case series.
Methods: The clinical and histopathological records of 
children with retinoblastoma seen from May 2004 to 
December 2005 were studied. Data was analysed for 
mode of presentation, laterality, clinical staging using 
Reese-Ellsworth (R-E) classification, histopathological 
high risk features (HHRF) for metastasis, and patient 
outcome.
Setting: Ophthalmology Unit, Korle-Bu Teaching 
Hospital, Ghana.
Results: Twenty-three patients presented with 
retinoblastoma over the period. Males were 12(52.2%). 
The age range from 1 to 84 months, mean 36.3(22.15) 
and median (36 months). Nineteen (82.6%) had 
unilateral and 4(17.4%) bilateral disease. The common 
clinical presentations were leukocoria in 20(87.0%), 
proptosis 8(34.8%), strabismus 5(21.7%) and red eye 
5(21.7%). The clinical features were commensurate 
with R-E stage V in 20(87.0%) patients, 2(8.7%) with 
orbital recurrence and 1(4.3%) with post-enucleation 
anophthalmos. HHRFs were present in 9(75%) 
enucleated eyes with invasion of optic nerve as the 
commonest site (7/9).  The patients were followed up 
for 1 day to 19 months. Eight abandoned treatment, 2 
were discharged for palliative treatment, 2 out of 5 
with metastasis died and 6 had no metastases at their 
last visit. Common sites for metastasis were the bone 
marrow, brain and orbit.
Conclusion: Majority of the patients presented with 
advanced disease manifesting as leukocoria, proptosis, 
RE stages V disease and poor outcome.
Keywords: leukocoria, metastasis,Reese-Ellsworth, 
retinoblastoma, tumour.
INTRODUCTION
Retinoblastoma is the commonest intraocular tumour in 
childhood affecting about 1 child in 20,000.1 It 
accounts for about 3% of cancers in children younger 
than 15 years of age.1 Untreated, retinoblastoma is 
almost uniformly fatal,2 but with availability of 
resources for early detection and treatment, the survival 
rate has improved from approximately 30% in the 
1930s to over 90% in the 1990s in developed 
countries.3,4,5,6 However, in developing countries, the 
majority of patients with retinoblastoma present with 
advanced disease with the resultant 5 year survival of 
less than 50%. 7,8,9 
The factors for this poor prognosis may include late 
presentation with a high mean age at diagnosis, 10,11
interval between onset and treatment of more than 5 
months, a lag time before treatment exceeding 2.5 
months, extraocular disease,12 higher occurrence of 
poorly differentiated tumours,13 presence of other 
histopathological high risk features (HHRF) for 
metastasis, and other factors such as lack of knowledge 
about the disease and its outcome, high costs of 
hospital care (diagnosis and treatment), and lack of 
resources for care. Improvement in survival in 
developing countries will require measures that 
enhance early reporting through health education,14
early and cheaper means of screening those at risk and 
early diagnosis of affected patients, as well as early, 
affordable and effective forms of treatment including 
means of funding such as national health insurance or 
government- funded schemes.15,16,17
At the Paediatric Department of Ghana’s premier 
teaching hospital, Korle Bu Teaching Hospital, Accra, 
retinoblastoma was found to be the second commonest 
childhood tumour after Burkitt’s lymphoma.18
Retinoblastoma was the commonest malignant 
intraocular childhood cancer seen at the Eye Clinic of 
the same hospital, and as elsewhere, and formed about 
50% of ocular tumours seen at the clinic.19 Only about 
38% of the retinoblastomas were diagnosed before the 
age of 3 years.19
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Unfortunately over a decade after this study, anecdotal 
observations showed that children with retinoblastoma 
attending the same clinic were increasingly presenting 
late with advanced disease and fatal outcomes and 
there had been no active intervention to address this 
trend.
As survival in patients with retinoblastoma is inversely 
related to the stage of the disease at presentation,20-24
we carried out this study to determine the stages of 
retinoblastoma in our patients at presentation and their 
relation to outcome. This will serve as baseline data for 
further studies and help plan interventions for 
improvement in survival.
MATERIALS AND METHOD
A retrospective case series of all children seen at the 
Korle-Bu Teaching Hospital Eye unit with a diagnosis 
of retinoblastoma, from May 2004 to December 2005, 
was determined from clinical and histopathological 
records of the hospital. Data was compiled on 
demographic characteristics, clinical examinations, 
investigations, histopathology findings, treatment given 
and their outcomes. The information was recorded on 
pre-designed forms. 
The initial evaluation of the children included complete 
ophthalmological and systemic examination in 
collaboration with the Paediatric Oncology Unit. The 
ophthalmological evaluation included visual acuity, slit 
lamp examination and dilated-fundus examination with 
scleral indentation under general anaesthesia. The 
systemic evaluation  included full blood count, lumbar 
puncture for cerebrospinal fluid (CSF) cytological 
analysis, bone marrow aspirations for tumour cells, 
chest x-rays and examination for other evidence of 
metastases. 
The basis of diagnosis of retinoblastoma was: a 
leukocoria associated with a retinal mass, with chalky 
areas, blood vessels coursing over it, with or without 
subretinal fluid, and or a proptosis preceded by a 
history of a ‘cat's eye’ or a shiny white spot in the eye. 
This was with or without confirmation by imaging 
studies i.e. C.T. scan or ultrasonography, looking for 
presence of calcifications in an intraocular mass arising 
from the retina. The clinical diagnosis could not be 
confirmed by imaging studies in some patients as they 
were not affordable to their carers. Treatment given 
included enucleation alone, chemotherapy and 
enucleation, or combined chemotherapy, enucleation 
and external beam radiation. Chemotherapy included 
vincristine, etoposide, carboplatin or cyclophos-
phamide and intrathecal methotrexate when indicated 
according to a local protocol.
Data was analysed for mode of presentation, laterality, 
clinical staging of disease using Reese-Ellsworth (R-E) 
classification (Box 1), presence of HHRF for 
metastasis in enucleated eyes and patient outcome.
Box1 Reese-Ellsworth Classification for 
Retinoblastoma25
Group I a. Solitary tumor, less than 4 disc diame-
ters in size, at or behind the equator
b. Multiple tumors, none over 4 disc di-
ameters in size, all at or behind the equa-
tor. 
Group II a. Solitary tumour, 4 to 10 disc diame-
ters in size, at or behind the equator.
b. Multiple tumors, 4 to 10 disc diame-
ters in size, all at or behind the equator.
Group III a. Any lesion anterior to the equator.
b. Solitary tumor larger than 10 disc di-
ameters in size behind the equator.
Group IV a. Multiple tumors, some larger than 10 
disc diameters.
b. Any lesion extending anterior to the 
ora serrata.
Group V a. Massive tumors involving over half 
the retina.
b. Vitreous seeding.
HHRF were uveal infiltration involving the iris, ciliary 
body or choroid, anterior chamber seeding, scleral or 
extra scleral infiltration and optic nerve invasion i.e. 
lamina cribrosa, retrolaminar or transection margin of 
optic nerve.
Patient outcome was defined as alive with metastases, 
without metastases or with second malignant 
neoplasm; or dead with metastases, with second 
malignant neoplasm or from other causes.
RESULTS 
Twenty-three patients were seen with retinoblastoma 
within this 20 month period. The male:female ratio was  
1.1:1. The age ranged from 1 to 84 months, with a 
mean of 36.3 (22.15) months and median of 36 
months. Nineteen (82.6%) patients had unilateral and 
4(17.4%), including a neonate, had bilateral disease. 
There was no trilateral retinoblastoma seen ). With 
regards to the bilateral cases, the parents of only one 
patient could be examined in an attempt to determine 
the inheritance pattern. They had normal ocular 
findings. The parents of the other 3 children abandoned 
treatment of their children as soon as the diagnoses 
were confirmed and counseling on the disease and its
management offered. Hence the inheritance pattern 
could not be ascertained.   
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The common presentations were leukocoria 20 
(87.0%), proptosis 8 (34.8%), strabismus 5 (21.7%) 
and red eye 5 (21.7%). Other presentations included 
fungating and necrotic orbital mass 2 (8.7%), 
buphthalmos with enlarged and cloudy cornea 2 (8.7%) 
flat anterior chamber 3 (13.1%), rubeosis 1 (4.4%), and 
hyphaema 1 (4.4%).
Table 1 Baseline Characteristics of Patients with 
Retinoblastoma
Total number 23
Interval between enucleation & metastasis (mths)
Range, Mean, SD 0.2-7, 5.72, 2.71
Investigations
CT Scan confirmation of
diagnosis (n=13)
- intraocular  
- extraocular (Optic Nerve.&  
Brain)                                                                                              
9 (69.2%)
4 (30.8%)
Ultrasonography (B mode)         
- intraocular       (n=1)                      1
Bone Marrow infiltration ( n=7) 4 (57.1%)
CSF (normal) (n= 4) 4 (100%)
Initial Treatment given 12 patients
Primary enucleation 7 (58.3%)




Histopathological High Risk Features (in 12 enu-
cleated eyes)
Presence of risk factors 9 (75%)
Unknown 1 (8.3%)
No Risk Factors 2 (16.7%)
Twenty patients (87.0%) presented with R-E stages V: 
3 with Va, 11 with Vb and 6 with Vb with orbital 
inflammation or extension; 2 (8.7%) others presented 
with orbital recurrence and 1 (4.3%) with post-
enucleation anophthalmos after treatment elsewhere 
with histology proven diagnosis.
Results of investigations for confirmation of diagnosis 
and for metastases are as illustrated in Table 1. 
One or more HHRF for metastasis were present in 9 
(75%) of the 12 enucleated eyes: invasion of optic 
nerve 4 including 1 transection margin, uveal 
infiltration 1, combined optic nerve and uveal 
infiltration 2, extra-scleral and orbital fat extension 1,  
and combined extra-scleral, uveal and optic nerve 
invasion 1.  
Seven of the enucleations were primary, for clinical 
diagnoses and treatment of intraocular retinoblastoma. 
Four of these showed HHRFs: invasion of optic nerve 
2, uvea 1, combined uvea and optic nerve 1. One 
patient whose histopathology report and specimen 
could not be traced, and also defaulted from follow up 
shortly after surgery, presented 9 months post surgery 
with orbital recurrence.   
The patients were followed up for 1 day to 19 months, 
mean 5.7 (SD5.67) and mode of 8 months. At the last 
follow up, which was variable, 6 alive were patients 
with no metastasis while 5 had metastasis.  At follow-
up periods of 3 and 6 months, 3 patients were alive 
including 1 with metastasis; at 12 months only 1 was 
alive without metastasis and at 18 months only one was 
alive with metastasis. Parents/carers of eight (34.8%) 
patients defaulted treatment, 2 (8.7%) were discharged 
home on account of advanced disease with financial
difficulty for palliative care at peripheral hospitals near 
their residential areas and 2 (8.7%) died with 
metastasis at 4 and 13months respectively. No second 
malignant tumour was seen (Table2).
The commonest site for metastasis was the bone 
marrow - 4 out of the total number of 7 patients who 
had metastasis (5 who were alive with metastasis and 2 
who died with metastasis). Other sites were the 
brain/CNS 2, orbit 2, and combined brain and orbit 1. 
One child with brain metastasis also showed metastases 
to the skull.
DISCUSSION 
This study showed that majority of the patients (82.6%) 
presented with unilateral retinoblastoma. This 
conforms with studies from both developed and 
developing countries although this proportion seems 
higher in our small series.9,10,16 The mean age of 
diagnosis was high at 36.3 months. This finding 
confirms observations from other developing countries 
in Africa and the Asia.9,10,20  A higher mean age at 
diagnosis has been found to be associated with 
advanced or metastatic retinoblastoma.21 This is in 
sharp contrast with the findings   from developed 
countries, where the mean age of diagnosis is less than 
24 months.5
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Table 2 Outcome in 23 patients with retinoblastoma 
Duration of fol-
low up (months)

















<3 8 (34.8) 1(4.3) 2 (8.7) 5(21.7)
3 6 (26.1) 2 (8.7) 1 (4.3) 2 (8.7) 1 (4.3) 
6 5 (21.7) 2 (8.7) 1 (4.3) 2 (8.7)
12 2 (8.7) 1 (4.3) 1 (4.3
18 2 (8.7) 1(4.3) 1 (4.3)
23 (100) 6(26.1) 5 (21.7) 10 (43.5) 2 (8.7)
The common clinical presentations of leukocoria, 
proptosis squint and red eye   from this study are also 
comparable to those in other developing 
countries.10,11,22-24 These features together with other 
signs such as, secondary glaucoma, fungating mass,
hyphaema and  flattened anterior chamber  are known 
signs of  advanced disease or high risk for 
metastasis.2,23  A study of 29 patients in Congo 
revealed the common presenting signs to be leukocoria, 
49%, followed by proptosis (28%). Other signs were 
strabismus, red eye, anterior scleral staphyloma, 
hyphema and buphthalmia.11 In Kenya, an analysis of 
470 oculo-orbital tumours demonstrated proptosis to be 
the hallmark, and the commonest manifestation at first 
attendance of orbital disease, with retinoblastoma being 
an important cause and that its presence depicted late 
or advanced disease.22 These studies show that 
proptosis, a late sign, is a common presentation of 
retinoblastoma in developing countries compared with 
the developed world11,22,24, a fact that validates the late 
or advanced presentation of most of our patients. 
A study in New Delhi, India, which reviewed 392 
patients with retinoblastoma, found all of them at 
presentation to have R-E grade V retinoblastoma, 
which represents advanced disease.24 Sahu et al in their 
retrospective study of 296 affected patients with 
retinoblastoma, over an 8 years period, in Mumbai, 
India, also found a predominance of advanced-stage 
disease with 74.5% presenting with Reese-Ellsworth 
group IV and V disease.20 These findings are supported 
by our study.
In Saudi Arabia, a study which assessed the value of 
various tests including bone marrow aspiration, lumbar 
puncture, and radionuclide scans, as part of the initial 
workup for metastases, found only 9.9% of the 101 
patients who had bone marrow studies with tumour 
infiltration, and 4.3% of the 94 patients with lumbar 
punctures yielding positive results.27 The rate of bone 
marrow metastasis is relatively high in our study, but 
this may be due to the small numbers in our study 
therefore we cannot make any meaningful comparison 
with this lager series from Saudi Arabia. Similarly, the 
percentage of our patients who had CSF analysis, or 
CT imaging is too small to allow any meaningful 
comparison.  The lack of confirmation of diagnoses 
with imaging studies and the inability to have full 
metastatic work-up for some of the patients, due to 
financial difficulties was also a significant limitation on 
final diagnoses and extent of tumour metastases. 
Consistent systematic investigations will be required in 
the future to allow such comparisons.
Optic nerve, choroid, extra scleral and anterior 
chamber infiltration are all recognized HHRFs for 
metastasis.26-32 Seventy-five percent of enucleated eyes 
in our series had one or more HHRF for metastasis. 
Optic nerve invasion was the commonest site of 
extraocular invasion in our series and correlates with 
that in other studies. 10
Our study has added to the importance of subjecting all 
enucleated eyes for histopathological analysis in order 
to identify those with HHRFs, the presence of which 
have adverse predictive value on prognosis.26-31
Progressively small numbers of patients continued with 
follow up thus for 12 and 18 months durations there 
were only 1 without metastasis and 1 with metastasis 
respectively.  
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This was also reflected in more than a third of the 
patients either abandoning treatment, 34.8%, or 
discharged with advanced disease and financial 
difficulty (8.7%), the latter group for palliative care at 
peripheral hospitals near their homes. In Honduras, a 
study assessing the impact of public education on the 
late diagnosis of retinoblastoma was carried out from 
July 1995 to January 2005. The study showed that the 
proportion of patients diagnosed with advanced 
retinoblastoma i.e. with extra-ocular disease, declined   
from 73% of the 59 diagnosed cases during the eight 
previous years (July 1995-June 2003) before the 
campaign, to only 35% of the 23 diagnosed cases 
during the post-campaign period (June 2003-January 
2005), (P = 0.002). However, more than one-third of 
patients in both time periods either refused therapy or 
abandoned treatment.33This high default rate identifies 
with our study.
We do acknowledge the limitations of this study. The 
small numbers analysed makes it difficult comparing 
our results with those from centres with larger series; 
similarly, it is impossible to make inferences for the 
whole population from this series. However the 
importance of the disease, being both sight and life 
threatening, renders the findings significant. Secondly, 
our centre is the only tertiary hospital in Ghana with a 
paediatric eye unit and thus the final referral point. 
This could explain the reason for all the patients 
encountered being those with advanced disease. Other 
general ophthalmologists in smaller or peripheral 
hospitals manage the less complicated cases by 
enucleation. This is because caretakers of the affected 
children sometimes refuse referrals to the bigger 
hospitals on account of long distance and cost. 
(Essuman V. Conversation with General 
Ophthalmologists: Regional Eyecare Planning 
Workshop, Accra, 12th May 2005).
Ghana has a population of about 22 million, with 41% 
(i.e.  9 million) being children less than 15years. Using 
a similar retinoblastoma age-standardized rate (ASR) 
from  Nigeria (7.4/million: IARC,1998) which shares 
similar geographic and demographic features in the 
West African Sub-region, implies that about 67 new 
cases of retinoblastoma should be seen in Ghana each 
year, of whom only 14 get to the Eye Unit of Korle-Bu 
each year (23 in 20 months). This suggests that about 
53 children per annum with retinoblastoma do not get 
to the tertiary centre at Korle-Bu. These patients may 
seek treatment from general ophthalmologists in the 
periphery or from alternate medical practitioners such 
as traditional healers and spiritualists.
It is of great interest to know how many of them get 
treatment in peripheral eye hospitals and the magnitude 
of retinoblastoma in the country. This requires further 
studies. A national register of childhood tumours, 
including retinoblastoma will be helpful.
In conclusion, majority of the patients presented with 
advanced disease manifesting as leukocoria, proptosis, 
R-E stages V disease and poor outcome. These findings 
have highlighted the late stage of presentation of 
patients with retinoblastoma in our hospital, problems 
with default and funding of treatment. Further studies 
are needed into: why they present late, the high default 
rate, ways of improving early reporting, cheaper ways 
of funding treatment, the magnitude of retinoblastoma 
in the country and how many of them seek treatment at 
peripheral hospitals from general ophthalmologists, in 
order to improve on survival. 
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